Fosun Pharma's subsidiary gets FDA nod for clinical trial

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced that its subsidiary, Shanghai Junji Health Technology Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials for LBP-ShC4, a novel, self-developed live biotherapeutic product intended for treating androgenetic alopecia (AGA). Junji Health will initiate Phase I clinical trials of LBP-ShC4 upon meeting the necessary conditions. As of April 2025, the cumulative R&D investment for LBP-ShC4 totaled CNY 0.17 billion. The company notes that, as of the announcement date, there are no approved live biotherapeutic products worldwide for treating AGA. The company also cautioned investors that the drug's development and potential market launch is subject to risks including clinical trial outcomes and regulatory approvals.